Abstract
The diagnosis and management of inflammatory bowel disease (IBD) in children and adolescents is a challenge to patients, their families, and to the healthcare team. This review highlights recent advances in the epidemiology, diagnosis, and management of pediatric IBD. Among the most prominent advances are the new diagnostic serologic assays that can help screen for IBD in the absence of physical signs of disease and help discriminate between ulcerative and Crohn's colitis. Other tests have been identified as potential noninvasive markers of disease activity, including color Doppler abdominal ultrasound and sugar permeability tests. Recent advances in pharmacogenetics afford clinicians the ability to optimize and individualize therapy using azathioprine or 6-mercaptopurine. Finally, bone health has come forth as a major issue in the complete management of pediatric IBD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Loftus EV Jr, Silverstein MD, Sandborn WJ, et al.: Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998, 114:1161–1168. This important epidemiologic study documents the incidence and prevalence of inflammatory bowel disease in a primarily white population of the United States between 1940 and 1993.
Ogunbi SO, Ransom JA, Sullivan K, et al.: Inflammatory bowel disease in African-American children living in Georgia. Pediatrics 1998, 138:103–107. This study demonstrates that the incidence of inflammatory bowel disease among African-American children is similar to that in other groups in North America.
Logan RFA: Inflammatory bowel disease incidence: up, down or unchanged. Gut 1998, 42:309–311. Very good review of the incidence of inflammatory bowel disease over the past decade, showing that Crohn's disease has increased, whereas ulcerative colitis has remained essentially unchanged.
Seidman E: Are serological tests for IBD useful to clinicians? Inflamm Bowel Dis 1999, 5:237.
Ruemmele FM, Targan S, Levy G, et al.: Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998, 115:822–829. This study validates ASCA and pANCA as specific markers for pediatric Crohn's disease and ulcerative colitis, respectively.
Hoffenberg E, Fidanza S, Sauaia A: Serologic testing for inflammatory bowel disease. J Pediatr 1999, 134:447–452.
Seidman EG, Dubinsky, M Patriquin, et al.: Recent developments in the diagnosis and management of pediatric IBD. In Trends in Inflammatory Bowel Disease Therapy 1999. Edited by CN Williams, et al. Dordrecht, Netherlands: Kluwer Academic Publisher; 2000:87–95. This report introduces two novel developments in pediatric inflammatory bowel disease. The first is the use of ASCA and pANCA assays to screen patients with nonspecific irritable bowel-like symptoms and a normal physical examination. The second is the use of color Doppler abdominal ultrasound to determine disease activity in pediatric Crohn's disease by measuring bowel wall vessel density.
Bousvaros A, Leichtner A, Zurakowski D, et al.: Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci 1999, 44:424–430. This study supports the concept that the pathogenesis of Crohn's disease is mediated, in part, by the excessive production of angiogenic growth factors. It provides preliminary evidence for the measurement of this factor as a marker of disease activity in pediatric Crohn's disease.
Miki K, Moore DJ, Butler RN, et al.: The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease. J Pediatr 1998; 133:750–754. This study demonstrates that patients with active Crohn's disease and extensive ulcerative colitis have increased intestinal permeability, which can be quantified using a sugar absorption test. Further study is required to discern whether this test is clinically useful in monitoring disease activity.
Pearson DC, May GR, Fick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995, 123:132–142.
Cuffari C, Théorêt Y, Latour S, Seidman EG: 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996, 39:401–406.
Lennard L: Clinical implications of thiopurine methyltransferase- optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998, 20:527–531.
Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713. This study establishes the usefulness of pharmacogenetics in treatment of inflammatory bowel disease using 6-MP or azathioprine. Genotyping for mutations of the TPMT enzyme identifies patients who are at significantly higher risk of bone marrow toxicity with these drugs. Metabolite measurements of 6-MP allow clinicians to individualize doses of these drugs, aiming to achieve therapeutic 6-TG levels, while avoiding hepatotoxic 6-MMP and myelotoxic 6-TG levels.
Herzog D, Bishop N, Glorieux F, Seidman EG: Interpretation of bone mineral density values in pediatric Crohn's disease. Inflamm Bowel Dis 1998, 4:261–267. This study illustrates the relatively high prevalence of low bone density among children and adolescents with Crohn's disease. It points out the need to interpret bone density scores in terms of bone or height age, rather than chronologic age, in view of bone maturation delay in a large percentage of such cases.
Seidman E: Nutritional therapy for Crohn's disease: lessons from the Ste-Justine Hospital experience. Inflamm Bowel Dis 1997, 3:49–53.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seidman, E.G. Recent advances in the diagnosis and treatment of pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2, 248–252 (2000). https://doi.org/10.1007/s11894-000-0068-y
Issue Date:
DOI: https://doi.org/10.1007/s11894-000-0068-y